Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kilitch Drugs (India) Limited ( (IN:KILITCH) ) just unveiled an announcement.
Kilitch Drugs (India) Limited has submitted to the stock exchanges a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31 March 2026. The certificate, issued by its registrar and share transfer agent MUFG Intime India Private Limited, confirms that securities received for dematerialisation during the quarter were duly processed, listed on the relevant exchanges, and that corresponding physical certificates were mutilated, cancelled, and replaced in the company’s register of members with the depositories as registered owners within prescribed timelines.
This disclosure underscores Kilitch Drugs’ adherence to regulatory requirements governing dematerialisation and share registry management, reinforcing operational transparency in its dealings with shareholders and market intermediaries. By confirming timely and proper handling of securities, the company and its registrar support investor confidence in the integrity of its share capital records and its compliance posture in India’s regulated capital markets.
More about Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited is an Indian pharmaceutical company engaged in the manufacture of drugs and formulations, with corporate and manufacturing facilities in Mumbai and Navi Mumbai. The company’s shares are listed on both BSE and the National Stock Exchange of India, giving it access to a broad base of public market investors.
Average Trading Volume: 3,008
Technical Sentiment Signal: Hold
Current Market Cap: 4.49B INR
For detailed information about KILITCH stock, go to TipRanks’ Stock Analysis page.